Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Madrigal Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (90)	4/5/2019 11:35:48 AM
From: Miljenko Zuanic	Respond to of 138

Thanks. It is not secret that wast majority of the NASH pts are obese/pre-diabetic/diabetic and they are already on medications (statins + TD2 drugs) that control lipids and glucose. Weight reduction is definitely PLUS. So, NASH candidates that will deal with NAFLD will/would be on top top the current treatment. In that light I was bit surprise on the restriction that they implemented for P3. It does not follow real world, IMO. Good things is that +450 subjects from first 900 will be F3, so it will be important to assess does controlling liver fat improve F in F-advance subjects, not only pre-fibrotic (F1). Still I am concern about length of the trial and placebo arm. Medical outcome is what count and contribute to economic value of the candidates.